


## Atuliflapon

## Chemical Properties

CAS No. :	2041075-86-7
Formula:	C <sub>24</sub> H <sub>26</sub> N <sub>6</sub> O <sub>3</sub>
Molecular Weight:	446.5
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Atuliflapon (AZD5718) is a novel 5-Lipoxygenase Activating Protein (FLAP) inhibitor for Treatment of Coronary Artery Disease.
Targets(IC50)	FLAP

## Solubility Information

Solubility	DMSO: 25 mg/mL (55.99 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.48 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2396 mL	11.1982 mL	22.3964 mL
5 mM	0.4479 mL	2.2396 mL	4.4793 mL
10 mM	0.224 mL	1.1198 mL	2.2396 mL
50 mM	0.0448 mL	0.224 mL	0.4479 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Ericsson H , Nelander K , Heijer M , et al. Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability[J]. Wiley-Blackwell Online Open, 9(3).

Ericsson H , Nelander K , Lagerstrom-Fermer M , et al. Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor: Initial Clinical Experience with AZD5718[J]. Clinical and Translational Science, 2018, 11(3).

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481